NASDAQ:ALQA Alliqua Biomedical (ALQA) Stock Price, News & Analysis → The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad) Free ALQA Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$2.20▼$3.2352-Week Range N/AVolume371,516 shsAverage Volume114,400 shsMarket Capitalization$13.46 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Alliqua Biomedical alerts: Email Address Ad Gold Safe ExchangeThe “Perfect Storm” for GoldGold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.Click here now to download the free Precious Metals Buying Guide! About Alliqua Biomedical Stock (NASDAQ:ALQA)Alliqua BioMedical, Inc. develops, manufactures, and markets high water content, electron beam cross-linked, and aqueous polymer hydrogels or gels used in wound care, medical diagnostics, transdermal drug delivery, and cosmetics in the United States. It also provides contract manufacturing services to the OEM market. The company is headquartered in Langhorne, Pennsylvania.Read More Ad Gold Safe ExchangeThe “Perfect Storm” for GoldGold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.Click here now to download the free Precious Metals Buying Guide! ALQA Stock News HeadlinesNo headlines for this company have been tracked by MarketBeat.com Receive ALQA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alliqua Biomedical and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/09/2016Today4/17/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & Medical Instruments Sub-IndustryN/A Current SymbolNASDAQ:ALQA CUSIPN/A CIK1054274 Webwww.alliqua.com Phone215-702-8550FaxN/AEmployees6Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,420,000.00 Net Margins-230.50% Pretax MarginN/A Return on Equity-71.73% Return on Assets-55.23% Debt Debt-to-Equity RatioN/A Current Ratio8.28 Quick Ratio8.17 Sales & Book Value Annual Sales$2.22 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$1.65 per share Price / BookN/AMiscellaneous Outstanding Shares5,010,000Free FloatN/AMarket Cap$13.46 million OptionableNot Optionable Beta2.03 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. David Ian Johnson (Age 61)Pres, CEO, Principal Financial Officer & Director Dr. Phillip D. Forman M.D. (Age 60)DPM, Exec. VP of Clinical Affairs Mr. Joseph M. Warusz (Age 63)CFO, Treasurer & Sec. Key CompetitorsNEXGELNASDAQ:NXGLMicrobot MedicalNASDAQ:MBOTGlucoTrackNASDAQ:GCTKPetVivoNASDAQ:PETVBiotricityNASDAQ:BTCYView All Competitors ALQA Stock Analysis - Frequently Asked Questions How were Alliqua Biomedical's earnings last quarter? Alliqua Biomedical Inc (NASDAQ:ALQA) released its quarterly earnings results on Tuesday, August, 9th. The company reported $0.50 EPS for the quarter, topping the consensus estimate of ($2.70) by $3.20. The business had revenue of $5.50 million for the quarter, compared to analysts' expectations of $5.38 million. Alliqua Biomedical had a negative trailing twelve-month return on equity of 71.73% and a negative net margin of 230.50%. When did Alliqua Biomedical's stock split? Alliqua Biomedical's stock reverse split on the morning of Friday, October 6th 2017. The 1-10 reverse split was announced on Thursday, October 5th 2017. The number of shares owned by shareholders was adjusted after the market closes on Thursday, October 5th 2017. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of Alliqua Biomedical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Alliqua Biomedical investors own include Palatin Technologies (PTN), ContraVir Pharmaceuticals (CTRV), Argos Therapeutics (ARGSQ), Consolidated Water (CWCO), Biopharmx (BPMX), Ritter Pharmaceuticals (RTTR), NVIDIA (NVDA), OPKO Health (OPK), Gilead Sciences (GILD) and Tonix Pharmaceuticals (TNXP). This page (NASDAQ:ALQA) was last updated on 4/18/2024 by MarketBeat.com Staff From Our Partners[Urgent!] Generational Wealth GameplanCrypto 101 MediaHe Is Giving Away BitcoinCrypto Swap ProfitsThe “Perfect Storm” for GoldGold Safe ExchangeUrgent alert: open this for a huge profit potentialTimothy SykesTop 5 AI Stocks to Buy for 2024Market Moving TrendsTop 5 Tech Stocks to Buy for 2024Daily Market AlertsBiden out June 13; Kamala won’t replace him?Paradigm PressYour Money is Not SafeAmerican Alternative Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alliqua Biomedical Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.